1. Home
  2. LGIH vs GERN Comparison

LGIH vs GERN Comparison

Compare LGIH & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LGI Homes Inc.

LGIH

LGI Homes Inc.

HOLD

Current Price

$40.56

Market Cap

1.1B

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.29

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGIH
GERN
Founded
2003
1990
Country
United States
United States
Employees
N/A
229
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
LGIH
GERN
Price
$40.56
$1.29
Analyst Decision
Hold
Hold
Analyst Count
5
3
Target Price
$75.90
$2.17
AVG Volume (30 Days)
415.7K
15.7M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.09
N/A
Revenue
$1,705,504,000.00
N/A
Revenue This Year
$2.32
$26.91
Revenue Next Year
$17.94
$43.75
P/E Ratio
$487.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.55
$1.04
52 Week High
$69.42
$2.01

Technical Indicators

Market Signals
Indicator
LGIH
GERN
Relative Strength Index (RSI) 39.15 32.86
Support Level $34.71 $1.24
Resistance Level $41.50 $1.49
Average True Range (ATR) 2.33 0.09
MACD -0.64 -0.02
Stochastic Oscillator 1.03 0.00

Price Performance

Historical Comparison
LGIH
GERN

About LGIH LGI Homes Inc.

LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: